We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+17.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.54B
AUM Growth
+$331M
Cap. Flow
-$396M
Cap. Flow %
-6.06%
Top 10 Hldgs %
39.82%
Holding
179
New
25
Increased
33
Reduced
89
Closed
18

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$49.7M
2
GEHC icon
GE HealthCare
GEHC
+$36.6M
3
MRNA icon
Moderna
MRNA
+$34.7M
4
BHVN icon
Biohaven
BHVN
+$33.4M
5
BSX icon
Boston Scientific
BSX
+$28M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$98.4M
2
UNH icon
UnitedHealth
UNH
+$64M
3
EVH icon
Evolent Health
EVH
+$36.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34.5M
5
HUM icon
Humana
HUM
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Industrials 0.83%
3 Energy 0.03%
4 Consumer Discretionary 0.02%
5 Communication Services 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HCA icon
51
HCA Healthcare
HCA
$82.1B
$41.2M 0.63%
152,178
-3,465
-2% -$856K
TMDX icon
52
Transmedics
TMDX
$2.55B
$41M 0.63%
518,890
-17,847
-3% -$1.08M
SRRK icon
53
Scholar Rock
SRRK
$6.27B
$40.8M 0.62%
2,168,925
+31,000
+1% +$385K
VEEV icon
54
Veeva Systems
VEEV
$32.4B
$37.5M 0.57%
195,013
-29,087
-13% -$5.48M
PRCT icon
55
Procept Biorobotics
PRCT
$1.1B
$37.1M 0.57%
885,346
-2,950
-0.3% -$100K
ZBH icon
56
Zimmer Biomet
ZBH
$17.4B
$34.2M 0.52%
281,088
-3,800
-1% -$424K
MOH icon
57
Molina Healthcare
MOH
$12B
$33.1M 0.51%
91,476
-66,962
-42% -$23.6M
CNC icon
58
Centene
CNC
$32.9B
$32.8M 0.5%
441,853
-2,190
-0.5% -$158K
LLY icon
59
Eli Lilly
LLY
$1.03T
$32.8M 0.5%
56,212
-25,329
-31% -$14.8M
COO icon
60
Cooper Companies
COO
$14B
$32.6M 0.5%
344,148
-2,120
-0.6% -$178K
GMED icon
61
Globus Medical
GMED
$10.4B
$32.4M 0.5%
607,772
-1,843
-0.3% -$89.8K
MRK icon
62
Merck
MRK
$308B
$31.6M 0.48%
290,206
-1,690
-0.6% -$175K
BMRN icon
63
BioMarin Pharmaceuticals
BMRN
$11.5B
$31.4M 0.48%
325,776
-24,112
-7% -$2.13M
ATRC icon
64
AtriCure
ATRC
$1.79B
$29.2M 0.45%
817,883
+70,323
+9% +$2.62M
CSTL icon
65
Castle Biosciences
CSTL
$725M
$26.6M 0.41%
1,232,378
+4,347
+0.4% +$76.5K
CI icon
66
Cigna
CI
$75.1B
$26.5M 0.41%
88,470
-37,032
-30% -$10.8M
COR icon
67
Cencora
COR
$59.6B
$25.9M 0.4%
126,126
+109,039
+638% +$21.3M
PRVA icon
68
Privia Health
PRVA
$3.32B
$24.2M 0.37%
1,051,696
-3,482
-0.3% -$77.9K
BDTX icon
69
Black Diamond Therapeutics
BDTX
$103M
$24M 0.37%
8,535,839
+400,000
+5% +$938K
SWAV
70
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$23.8M 0.36%
124,810
-129,469
-51% -$24.5M
SRPT icon
71
Sarepta Therapeutics
SRPT
$1.8B
$22.9M 0.35%
237,286
-4,466
-2% -$428K
WVE icon
72
Wave Life Sciences
WVE
$1.11B
$22.7M 0.35%
4,494,458
– –
HOLX
73
DELISTED
Hologic
HOLX
$20.7M 0.32%
289,864
-272
-0.1% -$18.9K
HCM icon
74
HUTCHMED
HCM
$1.94B
$20.4M 0.31%
1,131,111
-671,852
-37% -$12.2M
DHR icon
75
Danaher
DHR
$143B
$19.5M 0.3%
84,310
-69,699
-45% -$14.8M
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2023 Portfolio in Review

As of Q4 2023, Bellevue Group held 179 positions worth $6.54B, up 5.3% from $6.21B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $396M in Q4 2023, closing 18 positions and reducing 89 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $34.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Biohaven worth $46M.

  • Bellevue Group's largest Q4 2023 buy was Biohaven: 1,075,000 shares worth $46M.
  • Bellevue Group added most to Immunocore in Q4 2023, an estimated $49.7M increase.
  • Bellevue Group's biggest Q4 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $98.4M.
  • Bellevue Group fully exited Jazz Pharmaceuticals in Q4 2023, selling an estimated $34.5M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.54B portfolio in Q4 2023.
  • Bellevue Group opened 25 new positions and closed 18 in Q4 2023.
  • Bellevue Group's portfolio value rose 5.3% quarter-over-quarter to $6.54B.

Based on Bellevue Group's 13F filing for Q4 2023, filed 14 Feb 2024.